DOCS:NYSEDoximity, Inc. Analysis
Data as of 2026-06-11 - not real-time
$20.24
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Doximity trades at $20.24, well below its DCF fair value of $26.77, implying ~24% upside. The company posted $645M revenue (+5% YoY) with an exceptional 89% gross margin and $107M quarterly free cash flow, underscoring strong profitability. However, technicals show a bearish trend (price below the 20‑day, 50‑day and 200‑day SMAs) and high 30‑day volatility (~93%).
Recent analyst downgrades from Baird, Wells Fargo and Jefferies add short‑term pressure, yet the low debt load, cash balance of $748M and forward PE of 12.7 suggest the stock is fundamentally undervalued. The AI‑driven product rollout and expanding platform usage provide a growth catalyst that could drive earnings expansion. Overall, the stock offers a compelling risk‑adjusted upside for investors with a medium‑to‑long‑term horizon.
Recent analyst downgrades from Baird, Wells Fargo and Jefferies add short‑term pressure, yet the low debt load, cash balance of $748M and forward PE of 12.7 suggest the stock is fundamentally undervalued. The AI‑driven product rollout and expanding platform usage provide a growth catalyst that could drive earnings expansion. Overall, the stock offers a compelling risk‑adjusted upside for investors with a medium‑to‑long‑term horizon.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Recent downgrades from major analysts
- Bearish technical positioning below key moving averages
- Elevated short‑term volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF‑derived upside of ~24% and forward PE of 12.7 vs industry average
- Strong free cash flow generation ($107M quarterly) and high margins
- Revenue growth and AI product adoption driving earnings expansion
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Scalable digital platform for U.S. medical professionals
- Robust cash position ($748M) and minimal debt
- Sustained high gross margin (89%) and operating leverage
Key Metrics & Analysis
Financial Health
Revenue Growth5.10%
Profit Margin30.40%
P/E Ratio20.7
ROE19.28%
ROA11.61%
Debt/Equity1.07
P/B Ratio3.9
Op. Cash Flow$326.5M
Free Cash Flow$255.3M
Industry P/E24.7
Technical Analysis
TrendBearish
RSI41.8
Support$17.15
Resistance$26.49
MA 20$20.40
MA 50$22.57
MA 200$42.20
MACDBullish
VolumeDecreasing
Fear & Greed Index84.48
Valuation
Fair Value$26.77
Target Price$25.15
Upside/Downside24.26%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.78
Volatility93.48%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.